MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Kodu・Aktsiate loetelu・Lantheus Holdings Inc

Lantheus Holdings Inc

Suletud

SektorTervishoid

83.83 0.04

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

82.3

Max

84.11

Põhinäitajad
By Trading Economics
Sissetulek	26M 54M
Müük	23M 407M
P/E Sektori keskmine	23.95 63.808
Kasumimarginaal	13.296
Töötajad	1,193
EBITDA	31M 98M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+12.7% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. mai 2026

Turustatistika
By TradingEconomics
Turukapital	325M 5.3B
Eelmine avamishind	83.79
Eelmine sulgemishind	83.83

Uudiste sentiment

By Acuity

18%

82%

37 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

79.24 / 103.64 Toetus ja vastupanu

Lantheus Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. apr 2026, 23:26 UTC

Kuumad aktsiad

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16. apr 2026, 20:41 UTC

Suurimad hinnamuutused turgudel

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16. apr 2026, 23:49 UTC

Market Talk

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16. apr 2026, 23:45 UTC

Market Talk

Nikkei May Decline After Hitting Record High -- Market Talk

16. apr 2026, 23:33 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16. apr 2026, 22:51 UTC

Market Talk

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16. apr 2026, 22:08 UTC

Tulu

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16. apr 2026, 22:06 UTC

Tulu

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16. apr 2026, 22:06 UTC

Tulu

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16. apr 2026, 22:06 UTC

Tulu

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16. apr 2026, 22:06 UTC

Tulu

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16. apr 2026, 22:06 UTC

Tulu

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16. apr 2026, 20:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

16. apr 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

16. apr 2026, 20:50 UTC

Market Talk

Tulu

Health Care Roundup: Market Talk

16. apr 2026, 20:49 UTC

Tulu

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16. apr 2026, 20:43 UTC

Tulu

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16. apr 2026, 20:40 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

16. apr 2026, 20:40 UTC

Market Talk

Tulu

Netflix Says Engagement Quality Hits New High -- Market Talk

16. apr 2026, 20:30 UTC

Kuumad aktsiad

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16. apr 2026, 20:25 UTC

Tulu

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16. apr 2026, 20:23 UTC

Tulu

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16. apr 2026, 20:19 UTC

Tulu

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16. apr 2026, 20:17 UTC

Tulu

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16. apr 2026, 20:17 UTC

Tulu

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16. apr 2026, 20:16 UTC

Tulu

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16. apr 2026, 20:16 UTC

Tulu

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16. apr 2026, 20:16 UTC

Tulu

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16. apr 2026, 20:16 UTC

Tulu

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Võrdlus sarnastega

Hinnamuutus

Lantheus Holdings Inc Prognoos

Hinnasiht

By TipRanks

12.7% tõus

12 kuu keskmine prognoos

Keskmine 94.6 USD 12.7%

Kõrge 110 USD

Madal 85 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Lantheus Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Lantheus Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

79.24 / 103.64Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

37 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.